Pathologically, the FLT3-ITD mutation itself can elevate endogenous ROS levels in leukemic cells via multiple pathways, including STAT5 (17, 21), which likely accounts for the moderate CD80 expression in FLT3-ITD AML cells. This evidence concerns the gene CD80 and acute myeloid leukemia.